Nephrogenic systemic fibrosis: considerations for the cardiologist.
Neil M
NM
Rofsky
D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis; D019786:Gadolinium DTPA / Q000009:adverse effects; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000175:diagnosis / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D019028:Magnetic Resonance Imaging, Cine / Q000009:adverse effects*; D054989:Nephrogenic Fibrosing Dermopathy / Q000209:etiology*; D006435:Renal Dialysis; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000209:etiology; D016277:Ventricular Function, Left
D003287:Contrast Media; C064925:gadodiamide; D019786:Gadolinium DTPA